Radiolabeled drug-delivery and controlled-release nanocarriers for arthritis: Clinical evidence, kinetic modeling, radiation-safety challenges, and precision nanotheranostics.

Combining radiolabeled drug‑delivery systems with controlled‑release nanocarriers is a major step forward for precise nanotheranostics in rheumatoid arthritis. This research looks at how radiolabeled medicines move, spread, and are released inside inflamed joints. By using ideas from chemical reaction engineering, we can write mathematical models that predict where nanocarriers go over time, taking both drug‑release rates and radioactive decay into account. Safety analysis also needs careful modeling of the radiation dose that stays near the joint versus the dose that spreads through the whole body. The project plan shows how to simulate drug‑release curves with compartmental models and finite‑element analysis. These tools help us fine‑tune carrier features such as particle

size, surface chemistry, and how strongly a ligand binds to its receptor. A systematic kinetic study lets us describe the transport processes that cause nanocarriers to accumulate in arthritic joints. This builds a solid theoretical base for safer, more effective targeted treatments. The proposed method also supports the creation of predictive simulation tools that evaluate therapeutic performance, distribution in the body, and safety limits of multifunctional nanotheranostic systems under different physiological conditions.

Message: Hi FE, I need help with “Radiolabeled drug-delivery and controlled-release nanocarriers for arthritis: Clinical evidence, kinetic modeling, radiation-safety challenges, and precision nanotheranostics.” in “Chemical Engineering”